A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer

Jianqing Lin, Marianna Zahurak, Tomasz M. Beer, Charles J. Ryan, George Wilding, Paul Mathew, Michael Morris, Jennifer A. Callahan, Gilad Gordon, Steven D. Reich, Michael A. Carducci, Emmanuel S. Antonarakis

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Fingerprint Dive into the research topics of 'A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences